Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
461-480 of 1,782 trials

Chronic Spontaneous Urticaria: Omalizumab Treatment Intervals

We are studying whether adults with well-controlled chronic spontaneous urticaria can safely extend the time between omalizumab treatments while maintaining symptom control.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Heart Failure: Colchicine Study

We are investigating whether colchicine can improve health status in people with heart failure compared to a placebo. This study aims to see if it helps patients feel better based on specific health questionnaires.

Heart Failure with Preserved Ejection Fraction>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Menopausal Women with Breast Cancer: Prasterone Therapy

We are studying whether a vaginal treatment can improve urinary and vaginal symptoms in menopausal women with a history of breast cancer or those currently on hormone therapy. The goal is to see how this therapy affects their quality of life and overall wellbeing.

Breast CancerGenitourinary Syndrome of Menopause≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncologyUrology

Nicotinamide for OPA1 Dominant Optic Atrophy

We are studying whether nicotinamide (vitamin B3) is safe and effective for people with OPA1 Dominant Optic Atrophy. The trial will assess its impact on vision and overall quality of life.

Dominant Optic Atrophy>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurologyOphthalmology

Cystectomy Complications: Antifungal Treatment Study

We are testing whether a new antifungal medication can help reduce complications after radical cystectomy. This study compares the medication to a placebo to see if it makes a difference.

Fungal Infection3-6 monthsMonitoring phase (IV)Standard MedicinesInfectious DiseasesUrology

Clostridioides difficile Infection: EXL01 Treatment

We are studying a new oral treatment, EXL01, to see if it can help prevent the return of Clostridioides difficile infection in high-risk patients. The trial will evaluate its safety and effectiveness, along with its impact on digestive health and quality of life.

Recurrent Clostridioides difficile Infection>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesGastroenterologyInfectious Diseases

Mirikizumab for Children with Ulcerative Colitis or Crohn’s Disease

We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.

Crohn’s DiseaseUlcerative ColitisInflammatory Bowel DiseasesConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Breast Cancer Treatment: Chemotherapy vs. Endocrine Therapy

We are studying the effectiveness of chemotherapy compared to endocrine therapy for women with ER-positive HER2-negative metastatic breast cancer. This trial focuses on patients with specific health markers to determine the best treatment option.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Heart Failure: Optimizing Drug Levels

We are studying how blood levels of heart failure medications affect patient health. This research may help improve treatment plans for individuals with heart failure.

Chronic Heart Failure with Reduced Ejection Fraction>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

MK-5684 Therapies for Advanced Prostate Cancer

We are studying the safety and effectiveness of MK-5684-based treatments for men with metastatic castration-resistant prostate cancer. This research aims to find better options for managing this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesCost ReimbursementOncologyUrology

Postoperative Pain Management After Cardiac Surgery: NSAIDs Study

We are investigating whether nonsteroidal anti-inflammatory drugs can help reduce pain after cardiac surgery. This study will also look at how these medications affect recovery and overall quality of life.

Postoperative Pain After Cardiac Surgery>2 yearsMonitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Suicidal Thoughts: Nitrous Oxide Treatment in Emergencies

We are studying whether inhaling a mix of nitrous oxide and oxygen can reduce suicidal thoughts in patients at emergency departments. The trial also looks at its effects on anxiety and depression symptoms over time.

Suicidal Thoughts≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

Plaque Psoriasis: Bimekizumab Study

We are exploring how bimekizumab affects gene expression in people with moderate to severe plaque psoriasis. The study also looks at the safety of this treatment for those with or without psoriatic arthritis.

Plaque PsoriasisPsoriatic Arthritis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDermatologyRheumatology

Uterine Leiomyosarcoma: Post-Operative Chemotherapy Study

We are investigating whether adding chemotherapy after surgery helps patients with high-risk localized uterine leiomyosarcoma avoid relapse. This study compares the new treatment approach to standard observation care.

Uterine LeiomyosarcomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Immuno-OCT Imaging: Safety and Feasibility Study

We are exploring a new imaging technique using a tracer for patients undergoing endoscopy. The goal is to determine if this method is safe and effective for better visualization during procedures.

Barrett's EsophagusColon CarcinomaGastrointestinal DysplasiaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Chronic Lymphocytic Leukemia: New Triple Therapy Study

We are testing a new combination of medications for patients with high-risk chronic lymphocytic leukemia who haven't been treated before. The study aims to see if this new treatment can help keep the disease from progressing better than standard options.

High-Risk Hematological Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Preventing Diabetes After Kidney Transplant: GLP-1 Medication Study

We are testing whether GLP-1 receptor agonists can help reverse metabolic syndrome in patients on the kidney transplant waiting list. This study will evaluate changes in health and safety over 3 to 6 months.

Metabolic Syndrome in Kidney Transplant Patients3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Preventing Diabetes After Kidney Transplant: GLP-1 Treatment Study

We are studying whether a new medication can help prevent diabetes in patients immediately after receiving a kidney transplant. This trial looks at various health effects and safety over time.

Post-Kidney Transplant Diabetes>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDiabetologyNephrology

Ulcerative Colitis: Comparing Ustekinumab and Infliximab

We are studying whether a combination of two treatments helps people with moderate to severe ulcerative colitis achieve remission better than using each treatment alone.

Ulcerative Colitis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Repotrectinib for Advanced Cancers in Kids and Young Adults

We are studying a new treatment for children and young adults with advanced cancers that have specific genetic changes. The trial aims to evaluate how well it works and its safety.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics